Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been assigned an average rating of “Hold” from the five ratings firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $3.33.

Several brokerages have commented on SYRS. HC Wainwright reiterated a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, StockNews.com began coverage on Syros Pharmaceuticals in a research note on Saturday, December 7th. They set a “sell” rating on the stock.

Insider Transactions at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the transaction, the director now directly owns 41,070 shares in the company, valued at $11,088.90. This trade represents a 76.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 12.26% of the company’s stock.

Hedge Funds Weigh In On Syros Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Syros Pharmaceuticals by 21.3% in the 1st quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after purchasing an additional 163,234 shares during the period. Acadian Asset Management LLC raised its holdings in Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after purchasing an additional 17,416 shares during the period. Certuity LLC bought a new position in Syros Pharmaceuticals in the 2nd quarter worth $109,000. Finally, GSA Capital Partners LLP bought a new position in Syros Pharmaceuticals in the 3rd quarter worth $34,000. 91.47% of the stock is owned by institutional investors.

Syros Pharmaceuticals Stock Down 3.7 %

Shares of NASDAQ:SYRS opened at $0.24 on Friday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The firm has a market capitalization of $6.33 million, a P/E ratio of -0.08 and a beta of 1.33. The stock has a 50 day moving average price of $1.38 and a 200-day moving average price of $3.09. Syros Pharmaceuticals has a 52-week low of $0.18 and a 52-week high of $8.17.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the company posted ($1.35) earnings per share. As a group, equities research analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.